Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.75 USD | 0.00% | -0.13% | +2.04% |
2023 | NGM Biopharmaceuticals Says Phase 2b Trial of Potential Cirrhosis Treatment Meets Primary Endpoint | MT |
2023 | Alpine 4 Holdings, Inc.(NasdaqCM:ALPP) dropped from S&P Global BMI Index | CI |
Sales 2023 * | 112M 9.36B | Sales 2024 * | 64.46M 5.37B | Capitalization | 20.26M 1.69B |
---|---|---|---|---|---|
Net income 2023 * | - | Net income 2024 * | - | EV / Sales 2023 * | 0.18 x |
Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | 0.31 x |
P/E ratio 2023 * |
-
| P/E ratio 2024 * |
-
| Employees | 495 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 89.73% |
1 week | -0.13% | ||
Current month | +5.78% | ||
1 month | +2.35% | ||
3 months | +29.65% | ||
6 months | -12.38% | ||
Current year | +2.04% |
Managers | Title | Age | Since |
---|---|---|---|
Ian Kantrowitz
FOU | Founder | 44 | 22/14/22 |
Jeffrey Hail
FOU | Founder | 61 | 22/14/22 |
Kent Wilson
FOU | Founder | 51 | 22/14/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kent Wilson
FOU | Founder | 51 | 22/14/22 |
Ian Kantrowitz
FOU | Founder | 44 | 22/14/22 |
Gerry Garcia
CHM | Chairman | 43 | 02/21/02 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 0.75 | 0.00% | 20,553 |
25/24/25 | 0.75 | -3.72% | 59,355 |
24/24/24 | 0.779 | +1.30% | 19,150 |
23/24/23 | 0.769 | +2.53% | 26,363 |
22/24/22 | 0.75 | -0.13% | 55,138 |
Delayed Quote Nasdaq, April 27, 2024 at 02:00 am IST
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+2.04% | 20.26M | |
+12.06% | 107B | |
-0.62% | 29.43B | |
+12.05% | 22.21B | |
-16.05% | 17.75B | |
-6.34% | 17.25B | |
+8.74% | 15.28B | |
-4.89% | 12.2B | |
-2.85% | 10.42B | |
-8.86% | 9.04B |
- Stock Market
- Equities
- ALPP Stock